Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia 1Congenital Abnormalities 1

Interventions

venetoclax 2fludarabine phosphate 2Thiotepa 2Cyclophosphamide 2Busulfan 2cedazuridine 1Whole-Body Irradiation 1Stem Cell Transplantation 1Radiotherapy 1Methylprednisolone 1Methotrexate 1Melphalan 1Hematopoietic Stem Cell Transplantation 1Filgrastim 1Etoposide 1Cytarabine 1Cyclosporine 1Cladribine 1Carboplatin 1Azacitidine 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Leukemia, Myelomonocytic, Chronic × Hematopoietic Stem Cell Transplantation × Clear all
NCT04708054 2026-02-19

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

M.D. Anderson Cancer Center

Phase 2/3 Recruiting
324 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡